Pluri Inc. Expands Manufacturing Collaboration With Remedy Cell
I'm PortAI, I can summarize articles.
Pluri Inc. has expanded its collaboration with Remedy Cell Ltd., focusing on stem cell-derived therapeutics. The partnership has achieved key milestones, including implementing Remedy Cell’s manufacturing process at Pluri’s GMP facility and producing clinical-grade batches for an upcoming Phase 1b trial. PluriCDMO™ will continue to support Remedy Cell's clinical and pre-commercial programs, advancing cell-free biologics development. This news was generated by Public Technologies using AI and is for informational purposes only.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments